Isomorphic Adds To Growing AI War Chest With First External Funding Round

The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.

Artificial intelligence-focused biotech Isomorphic Labs is getting another big infusion of funding to further develop its drug-design system and also to advance some of its programs into the clinic, on top of partnerships with two major drug makers that it announced at the beginning of 2024. It also adds to a slew of financings, acquisitions and partnerships involving AI-based biotech companies throughout 2024.

London-based Isomorphic said 31 March that it raised $600m in its first external funding round, which Thrive Capital led, while...

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

18 Jul 2025

• By Vibha Ravi

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

09 Jul 2025

• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

03 Jul 2025

• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

24 Jun 2025

• By Kevin Grogan

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.